Previous reports have described intratumoral hemorrhage in HCC during atezo-bev (Table 2).4,5) Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), and its anti-VEGF effect is related to hemorrhagic risk.6) Ramucirumab, a VEGF receptor-2-targeting human immunoglobulin G monoclonal antibody, is also a therapeutic option for HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.